EP4 in the Malignant Cell {#s1}
=========================

The cyclooxygenase-2 (COX-2) enzyme catalyzes the rate-limiting step in the metabolism of arachidonic acid to prostaglandins. COX-2 is frequently overexpressed in epithelial malignancies and is associated with poor clinical outcomes. In cancer, the most abundant COX-2 product is prostaglandin E~2~ (PGE~2~) which binds four G-protein-coupled EP receptors (EP1--EP4) to activate several intracellular signaling pathways. EP4 is upregulated and contributes to the pathology of many human malignancies including those of the breast, prostate, colon, ovary, and lung ([@B33]; [@B21]; [@B40]). EP4 receptor signaling is linked to many properties of malignant cells including proliferation, migration, invasion, metastasis, angiogenesis, immune evasion, epithelial to mesenchymal transition, and cancer stem cell (CSC) properties. This review will summarize some of the growing evidence that EP4 contributes to cancer progression both in a tumor cell-autonomous manner and by modulating the behavior of EP4-positive host cells in the tumor microenvironment.

The Role of EP4 in Cell Proliferation {#s1_1}
-------------------------------------

Heightened EP4 expression supports the proliferation of some, but not all malignancies. Many mechanisms contribute to the growth-promoting properties of the PGE~2~/EP4 axis. Exposure of cultured cancer cell lines to PGE~2~ or specific EP4 agonists can lead to modest stimulation of cell growth; conversely, small molecule EP4 antagonists or EP4 gene targeting inhibits proliferation of some cell lines. For example, overexpression of EP4 in prostate cancer cells results in increased proliferation *in vitro* and in xenograft models ([@B42]). The pro-proliferative response is associated with the cAMP/PKA/PI3K-Akt signaling pathway ([@B48]). These findings support the continued investigation of EP4 as a potential target in castration-resistant prostate cancer. Mice transgenic for epithelial EP4 overexpression display more squamous cell carcinomas ([@B36]). An exception to the general conclusions regarding the tumor-promoting role of EP4 is in gastric carcinoma cell lines where administration of EP2 and EP4 *agonists* resulted in growth inhibition, decreased cell proliferation, and was accompanied by cAMP production. The possible role of EP antagonists was not investigated ([@B29]).

Elevated EP4 expression drives COX-2 expression and PGE~2~ secretion in uterine cervical cancer tissue, promoting colony formation and VEGF expression ([@B28]). In colorectal cancer, EP4 occupation leads to ERK activation supporting anchorage-independent growth and resistance to apoptosis that is reversed by small molecule EP4 antagonists ONO-AE3-208 and AH23848 ([@B5]). Likewise, inhibition of the EP2 and EP4 receptors (with AH6809 and GW627368X, respectively) represses IGF-1-induced proliferation of pancreatic BxPC-3 cancer cells ([@B38]) and is accompanied by increased phospho-PKC-θ and decreased phospho-ERK ([@B39]).

The Role of EP4 in Cell Migration/Invasion/Metastasis {#s1_2}
-----------------------------------------------------

Tumor dissemination is the chief cause of cancer mortality. Several early studies demonstrated that small molecule EP4 antagonists (AH23848; ONO-AE3-208) or EP4 gene silencing reduced metastatic potential *in vivo* in preclinical models of breast, prostate, colon, and lung cancer ([@B20]; [@B49]; [@B48]). The anti-metastatic activity is partially attributed to direct inhibition of tumor cell migration and invasion. For example, EP4-shRNA knockdown in lung cancer cells led to decreased cell migration *in vitro* by a β-arrestin1-dependent mechanism ([@B13]). EP4 blockade in prostate cancer cells overexpressing EP4 resulted in reduced migration, invasion, and metastasis. Down-regulation of EP4 and EP2 receptors or the EP4 antagonist AH23848 inhibit migration and invasion of human colorectal carcinoma cells ([@B10]). Conversely, agonism of EP4 promoted *in vitro* lung cancer cell migration ([@B13]). EP4 is coupled to several downstream signaling pathways. In prostate, colon, and renal cell carcinomas, EP4 supports cell proliferation and invasion *via* the cAMP-PKA/PI3K-AKT signaling pathway and this response is inhibited by L161982 ([@B50]) by ONO-AE3-208 or Cayman 10598 ([@B11]) or by RQ15986 ([@B21]). EP4 regulates cell migration through Orai1 Ca^2+^ signaling in human oral squamous carcinoma cell lines that is blocked by ONO-AE3-208; cancer metastasis was inhibited when EP4 gene expression was reduced ([@B30]). In melanoma, EP4 agonism induces cell migration accompanied by accumulation of β-catenin and decreased expression of several metalloproteinases ([@B44]). Knockdown of EP4 abolished the transendothelial migration and metastatic intravasation capacity in metastatic renal carcinoma ([@B50]). EP4 agonists can induce and the EP4 antagonist GW627368x blocks EGFR-dependent degradation of the extracellular matrix that, if left unchecked, facilitates breast cancer invasion ([@B43]).

The COX2/EP4 pathway is coupled to induction of several proinflammatory cytokines; several are tumor-promoting. In prostate cancer, the inhibitory effects of the EP4 antagonist AH23848 were linked to downregulation of several cytokines (CCL2, IL6, and CXCL8) ([@B4]). In a murine model of bone metastatic prostate cancer, the EP4 antagonist ONO-AE3-208 abrogated inflammation-dependent bone metastasis and bone loss ([@B47]). EP4 antagonism with the same compound also prevents bone loss in malignant melanoma cells *via* the suppression of osteoclasts ([@B41]).

Cancer Stem Cells and EP4 in Chemoresistance {#s1_3}
--------------------------------------------

More recently, EP4 has been implicated in treatment resistance and as a driver of CSCs. Epigenetic activation of the EP4 receptor may support resistance to endocrine therapy in patients with breast cancer that is reversed by GW627368x ([@B6]). Several labs have shown that EP4 is upregulated in malignant cells with stem-like properties and that treatment of tumor-bearing mice with EP4 antagonists (RQ15986, AH23848, Frondoside A) reduces the number of CSC ([@B15]; [@B22]). A positive feedback loop involving EP4/miR-526b and miR-655/COX-2 is critical to the mechanism by which EP4 supports breast CSC ([@B21]). Exposure of MCF7 cells to EP4 agonists upregulated both miR species and was accompanied by activation of PI3K/AKT, ERK, and NF-κB pathways leading to increased cell proliferation, migration, invasion, spheroid formation, and epithelial to mesenchymal transition. EP4 can mediate the effects of hypoxia-driven mesenchymal stem cells in the progression of hepatocellular carcinoma. This response is reversed in EP4 siRNA expressing cells or in the presence of GW627368x ([@B18]). The EP4 antagonist L161982 blocks the ability of enteric glial cells to stimulate colon CSCs *via* a PGE2/EP4/EGFR-dependent pathway ([@B45]). Although the exact mechanism by which EP4 antagonism allows for various cancer cells to transition from the mesenchymal/CSC state to an epithelial phenotype is not clear, one group has proposed that EP4 antagonism with GW627368x results in extracellular vesicle-mediated clearance of CSC markers, integrins, and drug transporters ([@B16]).

There is growing interest in the potential of EP4 antagonists in combination with other therapies, including chemotherapy. Gynecologic uterine smooth muscle tumors are sensitized to docetaxel in the presence of the EP4 antagonists AH23848 or RQ15986 ([@B32]). In a model of oxaliplatin-resistant colon cancer, EP4 blockade with L161982 inhibited CSC markers and tumorsphere formation ([@B8]). Likewise, cisplatin-resistant gastric cancer cells are sensitized to cisplatin *via* the suppression of COX-2/EP4/ERK1/2/P38 signaling by L161982 ([@B17]).

The Role of EP4 in the Host Response to Malignancy {#s2}
==================================================

Regulation of Lymphangiogenesis {#s2_1}
-------------------------------

In addition to tumor cell-autonomous roles for EP4, many host cells express EP4 and should be considered in the context of systemic EP4 targeting. EP4 plays a role in activation of PGE~2~ and COX-2 expression in rat mesenteric lymphatic endothelial cells ([@B27]). EP4 antagonism with RQ15986 inhibits tumor growth and angiogenesis in a murine model of breast cancer ([@B22]). In melanoma, PGE~2~ acts on EP4 expressed on fibroblasts in the tumor microenvironment to regulate the release of angiogenic factors ([@B9]).

Regulatory Function of EP4 on NK Cells {#s2_2}
--------------------------------------

Innate immunity plays a significant role in tumor control. Natural killer cells recognize and directly kill malignant cells and provide critical cytokines that promote the replication and activation of cytotoxic T lymphocytes. There are also critical interactions between NK and dendritic cells that further drive both innate and adaptive anti-tumor responses. Each of these functions is regulated by PGE~2~ acting on EP receptors expressed on the NK cell. While NK cells express each EP, the negative regulation by PGE~2~, in the context of malignancy, is through EP4 and EP2 ([@B14]; [@B7]; [@B19]). EP4 antagonists AH23848, ONO-AE3-208, Frondoside A and RQ15986, or to a lesser extent, the EP2 antagonist AH6809, prevent PGE~2~-mediated inhibition of NK cells.

In preclinical models of triple negative breast cancer, even when EP4 is directly inhibited in the malignant cell by shRNA targeting, the anti-metastatic activity is lost when NK cells are depleted in the host ([@B14]; [@B19]). NK cells isolated from either patients or tumor-bearing mice are compromised regarding the ability to lysis target cells, produce critical cytokines and to migrate in response to chemotactic signals. NK recognition and lytic activity is triggered by the presence of activating ligands and the loss of inhibitory signals on the target cells; the latter are delivered chiefly through the expression of MHC class I antigens on the target cell. EP4 antagonists including Frondoside A, reduce surface expression of MHC class I antigens and, at the same time, increase sensitivity to NK-mediated lysis ([@B7]). PGE~2~ prevents NKG2D, NCR, and CD16 activating receptors from triggering lysis ([@B25]). Thyroid cancer-derived PGE~2~ inhibits NK maturation as well as the expression of the NK receptors NK44, NK30, TRAIL, and NKG2D whereas NK inhibitory receptors are increased ([@B31]). Either EP2 (AH6809) or EP4 (AH23848) antagonists block the inhibitory actions of PGE~2~ on NK cells. Administration of EP4 antagonists (RQ15986, AH23848, Frondoside A) to tumor bearing mice restores the profound suppression of NK activity (cytotoxic functions, cytokine production, chemotactic activity), even in the context of progressive tumor growth ([@B7]; [@B19]). Thus, in both murine and human NK cells, the activating signals for lysis are reduced and the inhibitory signals are enhanced in response to PGE~2~ and these inhibitory signals are reversed by EP4 blockade. Importantly, the ability of NK cells to control metastasis is restored.

In addition to direct inhibitory effects of tumor-PGE~2~ on NK activities, myeloid-derived suppressor cells (MDSC) can also negatively regulate NK functions. MDSC derived from patients with advanced melanoma inhibit the activity of co-cultured NK cells ([@B23]). PGE~2~, acting on EP2 and EP4 receptors on the MDSC, activates p38 MAPK/ERK pathways leading to secretion of TGFβ to inhibit NK cells. This mechanism of immune suppression is blocked by AH6809 or AH23848. The critical role of PGE~2~ in regulating interactions between dendritic cells and NK cells was further elucidated in a recent study ([@B2]). In addition to MDSC regulating NK cells, NK cells can, in turn, recruit conventional type 1 dendritic cells that are critical to immune-mediated tumor control. cDC1 are recruited by the release of CCL5 and XCL1 from NK cells. The ability of PGE~2~ to compromise NK functions also results in impaired recruitment of cDC1 to the tumor microenvironment in a COX-2 dependent manner.

MDSC and M2 Macrophages Are Induced Through PGE2/EP Activation {#s2_3}
--------------------------------------------------------------

MDSC can become the dominant immune cell population in progressively growing tumors. PGE~2~ induces bone marrow stem cells to differentiate into Gr1+CD11b+ MDSCs but either EP2 (AH6809) or EP4 (AH23848) antagonists block the induction ([@B37]). In several tumor models, an EP4 antagonist (E7046) similarly blocked the induction of MDSC and M2 macrophages *in vivo* ([@B1]). Novel mechanisms by which PGE~2~/EP4 induces MDSC have been reported ([@B34]). PGE~2~ upregulates DNA methyl transferase 3A (DNMT3A) resulting in hypermethylation and repression of immune-promoting genes, specifically in the MDSC population. Conversely, inhibition of DNMT3A results in loss of this pattern of hypermethylation and loss of the immune suppressive properties of MDSC. The ability of PGE~2~ to induce DNMT3A and subsequent hypermethylation in MDSC was blocked in the presence of either EP2 (PF 04418948) or EP4 (L161982) inhibitors. Doxorubicin-resistant mammary tumor cells have higher levels of COX-2 and PGE~2~ secretion than the Dox-sensitive parental cells ([@B35]). These resistant cells more effectively induce MDSC and this induction is blocked by EP4 (ONO-AE3-208) or EP2 (AH6809) inhibitors. The microRNA miR-10a is key to the mechanism by which PGE~2~ induces MDSC through a PKA/AMPK-dependent signaling pathway.

PGE~2~ exerts anti-inflammatory activity on macrophages and monocytes. The EP4 antagonists L161,982 or CJ042794 inhibit LPS-induced production of TNFα by lung macrophages ([@B3]) or by expression of EP4 siRNA in human monocytic cells ([@B12]). The acute inflammatory response is supported by M1 macrophages whereas resolution of inflammation is driven by M2 phenotype macrophages. PGE~2~ plays a key role in the polarization of macrophages to the M2 phenotype resulting in poor induction of anti-tumor immunity. MicroRNA-21 negatively regulates M2 polarization by PGE~2~ ([@B46]).

Actions of EP Blockade on Cytotoxic T Cells and T Regulatory Cells {#s2_4}
------------------------------------------------------------------

Mammary epithelial COX-2-derived mediators contribute to pro-tumor immune function, particularly through T lymphocyte and cytotoxic immune cell function ([@B24]). EP4 inhibitors, as monotherapy, do not typically result in marked inhibition of tumor growth in preclinical models of breast, colon, or pancreatic cancer, among others. The modest inhibition of growth of breast tumors is, however, dependent on CD8+ T cells ([@B1]). The mechanism is not by direct actions of the EP4 inhibitor E7046 on either CD8+ T cells or on T regulatory cells; rather it is likely explained by blockade of MDSC actions. The demonstration that EP4 blockade appears to synergize with checkpoint inhibitor blockade with anti-CTLA-4 antibody or, alternatively, with direct targeting of T regulatory cells with an IL-2/diphtheria toxin fusion product is very promising. The latter combination therapy resulted in an inflamed tumor microenvironment expressing T cell activating and T cell recruiting chemokines including CXCL9, CXCL10, CXCL11, and Ccl5/RANTES and MIP-1α.

Future Directions {#s3}
=================

There is growing evidence that EP4 represents a novel therapeutic target in cancer, both expressed on the malignant cell as well as on EP4-positive host cells. It is likely that EP4 antagonists would be used in combination with either cytotoxic therapies or with other immune-modulating strategies (for excellent reviews see [@B21]; [@B40]). There is growing evidence that EP4 blockade can reverse chemotherapy resistance in several tumor types and therefore combinations of EP4 antagonists with standard of care chemotherapy should be considered. Combinations of EP4 inhibitors with immune therapies are also being considered. NK cells are particularly important in the control of metastatic disease and, in preclinical models, EP4 antagonists reduce tumor dissemination by an NK-cell-dependent mechanism. Primary tumor control appears to be more dependent on CD8+ T cells. These studies and others suggest that EP4 inhibitors may be more effective when combined with immune based therapies rather than as monotherapy. In support of future combination clinical trials, Albu et al. showed that EP4 antagonism combined with either Treg depletion or with an antibody to CTLA-4 provided superior tumor control to either monotherapy ([@B1]). Cancer clinical trials to evaluate EP4 inhibitors are recruiting in trials of Grapiprant (ARY-007) in combination with pembrolizumab in subjects with either advanced MSS colorectal cancers (NCT03658772) or, in a separate trial in advanced NSCLC (NCT03696212) ([@B26]; [@B40]). E7046 is being examined in a rectal cancer trial (NCT03152370) and BMS 986310 plus nivolumab is being investigated in a phase 1 trial in advanced solid tumors (NCT03661632). The possible role of EP4 in mediating resistance to endocrine therapies in breast cancer should also be explored further. Based on the ability of EP4 antagonists to inhibit CSCs and chemotherapy resistant cell lines, it is anticipated that clinical trials in these settings will also be forthcoming.
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